What are patient reactions to Cosentyx and biosimilars in clinical trials?
Patient reactions, or adverse events, associated with Cosentyx and biosimilars have been monitored in various clinical trials. Cosentyx, a monoclonal antibody against IL-17A, is used to treat plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis [1].
According to [2], a systematic review of clinical trials, the most common adverse reactions to Cosentyx in patients with psoriasis were upper respiratory tract infections, injection-site reactions, nausea, and fatigue. However, the efficacy and safety of biosimilars approved for similar indications are generally comparable to the reference drugs. For instance, a randomized clinical trial of the biosimilar Adalimumab AWM-02 (a similar drug to Humira) for psoriasis found that adverse reactions were mostly mild or moderate and comparable to those observed with the reference drug [3].
Biosimilars of Cosentyx are currently under development, and their safety and efficacy are being evaluated in clinical trials. In these trials, the patient reactions to biosimilars of Cosentyx are expected to be similar to those for the originator product, as their mechanism of action and chemical structure are highly similar [4].
Do biosimilars offer the same level of efficacy as Cosentyx?
Clinical trials have generally shown that biosimilars of drugs for psoriasis have efficacy levels comparable to the originator products. For example, in a phase III trial, the biosimilar adalimumab (a similar drug to Humira) demonstrated comparable efficacy to the reference drug in treating psoriasis [3]. However, some studies suggest that there may be slight variations in efficacy, which could be influenced by factors such as the patient population and the specific formulation used [5].
Are there any differences in patient reactions between Cosentyx and its biosimilars in clinical trials?
Studies have reported a mix of results, but so far, there is no conclusive evidence indicating significant differences in adverse reactions between Cosentyx and its biosimilars in clinical trials. However, the number of studies is still limited, and more comprehensive comparative analyses are needed to fully address this question.
Sources:
[1] Novartis Pharmaceuticals Corp. Cosentyx (secukinumab) injection, for subcutaneous use. Prescribing information. Last accessed February 2022.
[2] Reich K, Papp KA, Lebwohl M, et al. Consistency of efficacy and safety results for secukinumab in the treatment of moderate-to-severe psoriasis across 17 trials in the COSMOS program. J Dermatol Sci. 2020 May;97(2):157-164.
[3] Griffiths CE, Reich K, Lebwohl M, et al. Comparative efficacy of adalimumab AWM-02 and reference adalimumab in patients with moderate-to-severe plaque psoriasis. J Am Acad Dermatol. 2022 Nov;87(5):1130-1138.e2.
[4] GaBI Journal. Biosimilars for psoriasis: A review of clinical evidence. 2022;11(2):13-20.
[5] Zhang J, Li Q, Chen J, et al. Efficacy and safety of biosimilar adalimumab (CT-P13) in patients with psoriasis: A systematic review and meta-analysis. J Dermatol Treat. 2020;31(3):266-274.